Contract liabilities SPIC cash limit coverage SPIC insured amount Grants offset against general and administrative expenses Compensation Related Costs, Policy [Policy Text Block] Grants offset against research and development expenses Grants offset against operating expenses Net Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Investing Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Operating Activities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accounts Payable Increase (Decrease) in Prepaid Expense and Other Assets Comprehensive Income (Loss), Net of Tax, Attributable to Parent Operating Income (Loss) Liabilities, Current Assets, Current Shares underlying restricted stock units outstanding Schedule of estimated useful lives of principal classes of assets Foreign Operations NIH Grant Warrants Warrants Grants Grants Purchase of property and equipment in accrued expenses Deposits and other assets Sublease Storage Space [Member] Lessor [Member] Valencia CA [Member] Alameda CA [ Member] Performance or Market Conditions Vesting [Member] Equity Incentive Plans [Member] Second Sight Warrant Member Right Offering [Member] Biopharm Division [Member] Received grant Grant received funding period Term of warrants Outstanding warrants Description of stock option grant Cash paid for operating lease liabilities Lease agreement, effective date Clinical and regulatory expense Liquidated damages Common stock, par value Common shares issue Subsequent Event [Line Items] Subsequent Event [Table] Description of legal settlement Demanded damages, value Description of contract termination and claims Operating lease maintenance charges Operating lease cost Description of sub lease terms Description of lease Net lease agreement description Lease terminates Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Table] The element represents shares underlying restricted stock unit outstanding. The element represents nh grant policy text block. The element represents grants against operating expense. The element represents grants against operating general and administrative expense. Uncertain tax positions Reductions based on tax positions related to prior years Increases based on tax positions related to the current year Reserve for uncertain income tax positions Total R&E related deferred income tax assets (net of applicable amortization) State R&D carry-forward, no expiration date Federal R&D tax credit carry-forward, begin expiring in 2036 Post TCJA period federal NOL carry-forward, with no carry-forward limitation Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030 State tax (benefit), net of federal tax benefit (percent) Change in Valuation Allowance for the Year Ended R&D credit Net operating loss Stock compensation Lease ROU Capitalized R&E §174 Accruals and reserves Description of share-based payment arrangement Stock option, consecutive days Stock options, per share Stock options, share Number of shares that may be issued The element represents grants against operating research and development expense. Issuance shares of common stock Description of equity incentive plans Expected term The element represents cash spic insured amount. Allocated share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Options exercisable, number of shares (in shares) Exercised Granted Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Employer contributions to plan The element represents spic cash limit coverage. The element represents foreign operations policy text block. Share price (in dollars per share) Subsidiary, Sale of Stock [Line Items] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] The element represents biopharm division member. The element represents contract liabilities other. The element represents grants text block. The element represents grant received to support clinical development. The element represents grant received funding period. The element represents warrant disclosure text block. The element represents class of warrants or rights term. Class of Warrant or Right [Line Items] Class of Warrant or Right [Table] The element represents right offering member. Preferred stock, shares issued The element represents second sight warrant member. The element represents class of warrant or right outstanding1. The following table summarizes supplemental balance sheet information related to the Company’s operating leases (in thousands): Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Subsequent Event Type [Axis] Subsequent Event [Member] Geographical [Axis] Legal Entity [Axis] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Leasehold Improvements [Member] Asset Class [Axis] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Sale of Stock [Axis] Class of Warrant or Right [Axis] Plan Name [Axis] Title of Individual [Axis] Board of Directors Chairman [Member] Income Statement Location [Axis] Research and Development Expense [Member] Award Type [Axis] Share-Based Payment Arrangement [Member] Financial Instrument [Axis] Options Held [Member] General and Administrative Expense [Member] Lease Contractual Term [Axis] Class of Warrant or Right Outstanding1 Segments [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Establishment of operating right-of-use assets through operating lease obligations Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Grant receivable with intent to fund early feasibility clinical trial for five years Trading Symbol Security Exchange Name The element represents schedule of estimated useful life of property and equipment table text block. The element represents grant receivable to fund early feasibility clinical trial for five years. Stock option, grant year Options outstanding at beginning (in years) Weighted average period (in years) Unrecognized compensation cost Options exercisable (in dollars per share) Title of 12(g) Security Expected volatility Security Reporting Obligation Expected dividend yield Risk-free interest rate Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Outstanding at ending, weighted average grant date fair value (in dollars per share) Annual Information Form Outstanding at ending, number of shares (in shares) Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Cash and cash equivalents Prepaid expenses and other current assets Total current assets Warrant Disclosure [Text Block] LIABILITIES AND STOCKHOLDERS’ EQUITY Accounts payable Accrued expenses Litigation accrual Accrued compensation expense Total current liabilities Preferred stock, par value $0.0001 per share; 10,000 shares authorized; none outstanding Additional paid-in capital Accumulated deficit Preferred stock, par value (in dollars per share) Preferred stock, shares authorized Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] General and administrative, net of grants Total operating expenses Loss from operations Grants [Text Block] Outstanding at beginning, weighted average grant date fair value (in dollars per share) The element represents purchase of property and equipment in accrued expenses. Comprehensive loss Statement [Table] Statement [Line Items] Beginning balance (in shares) Stock-based compensation expense The element represents liquidated damages paid value. Ending balance (in shares) Statement of Cash Flows [Abstract] Stock-based compensation Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued compensation expenses Accrued expenses Net cash used in operating activities Purchases of property and equipment Net cash used in investing activities The element represents description of stock option grant. Net cash provided by financing activities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Operations Accounting Policies [Abstract] Fair Value Disclosures [Abstract] Fair Value Measurements Equity [Abstract] Equity Securities Retirement Benefits [Abstract] Employee Benefit Plans Share-Based Payment Arrangement [Abstract] Stock-Based Compensation The element represents deposits and other assets. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Event Principles of Consolidation Use of Estimates Cash, Cash Equivalents and Restricted Cash Outstanding at beginning, number of shares (in shares) Options exercisable period (in years) Research and Development Options exercisable, weighted average exercise price (in dollars per share) Patent Costs The element represents performance or market conditions vesting member. Concentration of Credit Risk The element represents equity incentive plans member. Stock-Based Compensation Comprehensive Loss Foreign Currency Translation and Transaction Gains and Losses Net Loss per Share Operating Segments Recently Adopted Accounting Standards Options outstanding at ending, vested and expected to vest (in years) Schedule of Money Market Funds at their Level within the Fair Value Hierarchy Summary of Warrant Activity Summary of Stock Option Activity Stock-based Compensation Expense The Company has the following activity relating to unrecognized tax benefits (in thousands): Other information related to leases are as follows (in thousands): Options outstanding at ending, vested and expected to vest (in dollars per share) The element represents clinical and regulatory expense. Options outstanding at ending, number of shares (in shares) Other adjustment, weighted average exercise price (in dollars per share) The element represents lessor member. The element represent lease effective date. The element represents cash paid for operating lease liabilities. Other adjustment Common stock issued Description of purchase agreement Forfeited or expired, weighted average exercise price (in dollars per share) Forfeited or expired Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated useful lives Restricted cash and cash equivalents Research and development costs Patent costs Exercised, weighted average exercise price (in dollars per share) FDIC insured amount Granted, weighted average exercise price (in dollars per share) Options outstanding at beginning, weighted average exercise price (in dollars per share) Options outstanding at beginning, number of shares (in shares) Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Weighted average exercise price Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Operating expenses Fair Value, Recurring and Nonrecurring [Table] Money market funds A summary of restricted stock activity and related information (in thousands, except per share data): Effect of exchange rate changes on cash and cash equivalents Adjustments to reconcile net loss to net cash used in operating activities: Shares underlying stock options outstanding The element represents establishment of operating right of use assets through operating lease obligations. Insider Trading Arrangements [Line Items] Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] All Trading Arrangements [Member] Individual [Axis] All Individuals [Member] Trading Arrangement, Securities Aggregate Available Amount Trading Arrangement Duration Trading Arrangement Expiration Date Trading Arrangement Termination Date Non-Rule 10b5-1 Arrangement Terminated [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Adopted [Flag] Trading Arrangement, Individual Title Trading Arrangement, Individual Name Material Terms of Trading Arrangement [Text Block] Statement of Stockholders' Equity [Abstract] Equity Component [Domain] Total The element represents shares underlying rsu's. Shares Underlying Rsus Property and equipment, net Property and equipment, net Property and equipment, gross Property Plant and Equipment Gross Gross deferred tax assets Deferred Tax Assets Gross Deferred Tax Assets, Valuation Allowance Valuation Allowance Property Plant And Equipment By Type [Axis] Property Plant And Equipment Type [Domain] Short-Term Debt [Text Block] Insurance Premium Financing Short-Term Debt [Table] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Domain] Loans Payable [Member] Short-Term Debt [Line Items] Number of Periodic Payments The number of periodic payments of debt instrument under the debt agreement. Number of periodic payments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Debt Instrument, Face Amount Debt instrument, principal amount Short-Term Debt, Percentage Bearing Fixed Interest Rate Debt instrument, interest rate Short-Term Debt Debt instrument, outstanding amount Statistical Measurement [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Valuation date stock price Award Type [Domain] All Award Types Percentage of Patients do not Take their Medicine as Prescribed in Real World Percentage of patients do not take their medicine as prescribed in real world The percentage of the patients do not take their medicine as prescribed in the real world. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Subsequent Event Type [Domain] Percentage of Patients Taking Wegovy (Semaglutide Injectable) Discontinue Therapy within First Year of Treatment Percentage of patients taking Wegovy (semaglutide injectable) discontinue therapy within first year of treatment The percentage of the patients whom taking Wegovy (semaglutide injectable) discontinue therapy within first year of treatment. Period for Delivering Therapeutic Drug Levels Period for delivering therapeutic drug levels The period for delivering therapeutic drug levels for medication adherence. Consolidated Entities [Axis] Consolidated Entities [Domain] Cortigent, Inc. [Member] Cortigent, Inc. [Member] This member stands for the information pertaining to "Cortigent, Inc.". Amount Agreed to Pay by Related Party Amount agreed to pay by related party The amount which has agreed to pay by related party upon agreement. Notes Payable, Other Payables [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Sale of Stock [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Share-Based Payment Award, Performance Vesting Criteria, Threshold Consecutive Trading Days Share-based payment award, performance vesting criteria, threshold consecutive trading days The threshold period of specified consecutive trading days within which common stock price would be required to be attained for the performance vesting criteria, based on market conditions in share-based payment arrangement. Plan Name [Domain] Title and Position [Domain] Statement of Income Location, Balance [Domain] Financial Instruments [Domain] Share-Based Payment Award, Percentage of Award Shall Vest on Hurdle Achievement Date Subject to Achievement of Performance Condition Percentage of award shall vest on hurdle achievement date subject to achievement of performance condition The percentage of award shall vest on hurdle achievement date subject to achievement of performance condition in share-based payment arrangement. Share-Based Payment Award, Percentage of Award Shall Vest First Anniversary after Hurdle Achievement Date Subject to Achievement of Performance Condition Percentage of award shall vest first anniversary after hurdle achievement date subject to achievement of performance condition The percentage of award shall vest first anniversary after hurdle achievement date subject to achievement of performance condition in share-based payment arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Including Subsequent Period to Performance Period End Date Share-based payment award, award vesting period including subsequent period to performance period end date The award vesting period including subsequent period to performance period end date over which grantee's right to exercise award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Share-Based Payment Award, Forecasted Stock Price, Specified Period Per Year Share-based payment award, forecasted stock price, specified period per year The specified period per year for forecasted common stock price using the valuation assumptions in share-based payment arrangement. Share-Based Payment Award, Performance Vesting Criteria, Stock Price Trigger Share-based payment award, performance vesting criteria, stock price trigger The share price of the entity's common stock which would be required to be attained for the performance vesting criteria, based on market conditions in share-based payment arrangement. Share-Based Payment Award, Percentage of Award Shall Vest Second Anniversary after Hurdle Achievement Date Subject to Achievement of Performance Condition Percentage of award shall vest second anniversary after hurdle achievement date subject to achievement of performance condition The percentage of award shall vest second anniversary after hurdle achievement date subject to achievement of performance condition in share-based payment arrangement. Stock Options With Market Conditions Vesting [Member] Maximum Period for Lease Term Which are Not Recorded on Balance Sheet Lease term which are not recorded on the balance sheet The maximum period for lease term which are not recorded on the balance sheet, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lease Contractual Term [Domain] Percentage of Weight Loss after Exenatide Implant Therapy for Patients Whom has High-Fat Diet-Induced Obese Mice Percentage of weight loss after exenatide implant therapy for patients whom has high-fat diet-induced obese mice The percentage of weight loss after exenatide implant therapy for patients whom has high-fat diet-induced obese mice. Period of Sham Implant Control Therapy Period of sham implant control therapy The period for sham implant control therapy. Sale of Common Stock At-Market offering, Authorized, Amount Aggregate offering price The amount authorized for sale of common shares in connection with at-the-market offering. Securities Purchase Agreement [Member] The element represents securities purchase agreement. Counterparty Name [Axis] Counterparty Name [Domain] Sales Agreement [Member] The element represents sales agreement. Jefferies Llc [Member] The element represents Jefferies Llc Period of Specific Therapy with Single Administration Period of specific therapy with a single administration The period for specific therapy with a single administration. Percentage of Liver Fat Reduction after Exenatide Implant Therapy for Patients Whom has High-Fat Diet-Induced Obese Mice Percentage of liver fat reduction after exenatide implant therapy for patients whom has high-fat diet-induced obese mice The percentage of liver fat reduction after exenatide implant therapy for patients whom has high-fat diet-induced obese mice. Revenue from Contract with Customer, Including Assessed Tax Proceeds from Issuance of Common Stock and Warrants in Connection with Securities Purchase Agreement, Gross Gross proceeds The gross proceeds of cash inflow from issuance of common stock and warrants in connection with securities purchase agreement during the reporting period. Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Issued The weighted average price per share amount at which grantees can acquire shares of common stock by exercise of warrants. Asset Class [Domain] Certificates of Deposit [Member] Fair Value Hierarchy and NAV [Domain] Measurement Frequency [Domain] Current operating lease liabilities Lease liability, current portion Proceeds from Issuance of Private Placement Gross proceeds from the private sale transaction Accumulated Other Comprehensive Income [Member] Accumulated Deficit [Member] Stock Issued During Period Value Issuance Of Common Stock In Connection With Private Purchase Net Of Issuance Costs The value of stock issued during the period upon issuance of common stock in connection with private purchase, net of issuance costs. Issuance of common stock in connection with private purchase, net of issuance costs Proceeds From Issuance Of Common Stock In Connection With Director Private Securities Purchase Agreement Net Of Issuance Costs The cash inflow from the issuance of common stock in connection with director private securities purchase agreement, net of issuance costs during the reporting period. Proceeds from issuance of common stock in connection with director private securities purchase agreement, net of issuance costs Director [Member] Geographical [Domain] AUSTRALIA Common stock, par or stated value per share Common stock, par value (in dollars per share) Warrants and Rights Outstanding, Term Warrant term Sales Of Common Stock In Connection With Private Sale Price Per Share Per share amount received in connection with private Sale. Sales of common stock in connection with private sale, price per share Proceeds From Sales Of Common Stock In Connection With Private Sale Gross The gross proceeds of cash inflow from the issuance of common stock in connection with private securities purchase agreement during the reporting period. Proceeds from sales of common stock in connection with private sale, gross Number Of Study Centre Represents the number of study centre Screening and enrollment of liberate-1, number of study centre Sales Of Common Stock Number Of Shares Issued In Connection With Private Sale The number of shares issued or sold in connection with private sale. Sales of common stock in connection with private sale Entity [Domain] Operating Loss Carryforwards [Table] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Operating Loss Carryforwards [Line Items] Research tax credit carryfowarrds for california state Research and development credit carryforwards Federal tax (benefit) at statutory rate (percent) Expected federal statutory tax rate Unrecognized Tax Benefits Balance at end of year Balance at beginning of year Unrecognized tax benefits Research and development credit carryforwards expiry period A description of the time period when research and development tax credit carry forwards expire. Deferred Tax Assets Tax Credit Carryforwards Research And Development Expiry Period Stock Issued During Period Shares Issuance Of Common Stock In Connection With Private Purchase Net Of Issuance Costs The number of shares issued during the period upon issuance of common stock in connection with private purchase, net of issuance costs. Issuance of common stock in connection with private purchase, net of issuance costs (in shares) Right-of-use assets Operating lease right-of-use assets, net Number of warrants convertible Number of securities called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Percentage Of Aggregate Proceeds Raised From Sale Of Securities For Cash Fee Payment To Placement Agency Percentage of the aggregate proceeds raised from the sale of securities for cash fee payment to placement agency The percentage of the aggregate proceeds raised from the sale of securities for cash fee payment to placement agency under agreement. Maxim Group Llc [Member] Maxim Group LLC (“Maxim”) [Member] This member stands for the information pertaining to "Maxim Group LLC (“Maxim”)". Legal Fees Legal expenses, maximum payment under agreement Stock, Class of Stock [Table] Class of Stock [Line Items] Payments of Stock Issuance Costs Stock issuance costs Securities Purchased under Agreements to Resell, Setoff Rights, Description Description of purchase agreement Insurance Premium Financing Property and Equipment Fair Value of Financial Instruments Computer Equipment [Member] Computer software Computer hardware and software Construction in Progress [Member] Construction in progress Furniture, fixtures and equipment Furniture and Fixtures [Member] Furniture and fixtures Lab equipment Equipment [Member] Equipment Number of Operating Segments Number of operating segments Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-based payment award, award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments Share-based payment award, fair value assumptions, expected dividend payments Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Share-based payment award, award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Grant Date Fair Value The weighted average grant-date fair value of share-based payment awards granted during the reporting period as calculated by applying the disclosed pricing methodology upon fair value assumptions. Share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average grant date fair value Federal tax (benefit) at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Current Federal, State and Local, Tax Expense (Benefit) State tax (benefit), net of federal tax benefit R&D tax credit from current year Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Internal Revenue Service (IRS) [Member] Federal [Member] Area of Real Estate Property Area of building property CURRENT ASSETS: CURRENT LIABILITIES: Lease liability, noncurrent portion Liabilities TOTAL LIABILITIES STOCKHOLDERS' EQUITY: Equity, Attributable to Parent TOTAL STOCKHOLDERS' EQUITY Beginning balance, value Ending balance, value Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Earnings Per Share, Basic Net loss per common share - basic (in dollars per share) Earnings Per Share, Diluted Net loss per common share - diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average shares outstanding - diluted (in shares) CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM FINANCING ACTIVITIES: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Income taxes paid NON-CASH INVESTING AND FINANCING ACTIVITIES: Investment in subsidiary Deferred Tax Liabilities, Investment in Noncontrolled Affiliates Deferred Tax Liabilities, Gross Gross deferred tax liabilities Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Segment Reporting Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment reporting information, by segment Schedule of Segment Reporting Information, by Segment [Table] Segments [Domain] Segment Reporting Information [Line Items] Operating expenses: Operating expenses: Labor and Related Expense Personnel and related expenses Research and development, net of grants Development expenses The cash inflow from insurance premium loan gross. Gross proceeds from insurance premium loan Proceeds From Insurance Premium Loan Gross Repayments Of Principal For Insurance Premium Loan Classified As Financing Activities The cash outflow to repay principal for insurance premium loan, classified as financing activities. Principal payment for insurance premium loan Segment net loss Net loss Net loss General and administrative expenses General and administrative, net of grants Other General and Administrative Expense Other general and administrative expenses Lease Expiration Date Lease expiration date Lessee, Operating Lease, Liability, to be Paid, after Year Five Thereafter Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Lessee, Operating Lease, Liability, to be Paid Total lease payments Weighted average discount rate Weighted average remaining lease term Income Taxes Income Tax [Policy Text Block] California [Member] California Franchise Tax Board [Member] Common Stock, Capital Shares Reserved for Future Issuance Income Taxes Income Tax Disclosure [Text Block] Income Taxes Deferred Tax Liabilities, Property, Plant and Equipment Accumulated depreciation and amortization Deferred Tax Assets, Net Total Deferred Tax Assets, Net Rental payments Office space rental related expenses Expected grants available to offset future operating expenses The amount of grants available to offset future operating expenses. Grants Available To Offset Future Operating Expenses Development expenses The amount of expense arising from the development related activity of reporting entity. Development Expense his member stands for the information pertaining to stock options with service vesting. Stock Options With Service Vesting [Member] Stock Options With Service Vesting [Member] Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted [Flag] Insider Trading Policies and Procedures Not Adopted [Text Block] Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] The number of weeks before being randomized to receive a therapy. Number of weeks before being randomized to receive a therapy Number of Weeks before being Randomized to Receive Therapy The number of weeks for weekly semaglutide injections therapy. Number of weeks for weekly semaglutide injections therapy Number of Weeks for Weekly Semaglutide Injections Therapy Nano Precision Medical Inc Warrant [Member] Shares underlying warrants outstanding Number of securities called by each warrant Summary of Significant Accounting Policies Lessor, Operating Lease, Term of Contract Lease Term Stock Issued During Period Value Issuance Of Common Stock And Warrants In Connection With Securities Purchase Agreement Net Of Issuance Costs The value of stock issued during the period upon issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs. Issuance of common stock and warrants in connection with Securities Purchase Agreement, net of issuance costs Stock Issued During Period, Shares, Issuance of Common Stock and Warrants in Connection with Securities Purchase Agreement, Net of Issuance The number of shares issued during the period upon issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs. Issuance of common stock and warrants in connection with Securities Purchase Agreement, net of issuance costs (in shares) Stock Issued During Period, Shares, Issuance of Common Stock and Warrants in Connection with Securities Purchase Agreement, Net of Issuance Costs Stock Issued During Period Value Issuance Of Common Stock And Warrants In Connection With At Market Offering Net Of Issuance Costs The value of stock issued during the period upon issuance of common stock and warrants in connection with at-the-market offering, net of issuance costs. Issuance of common stock in connection with the Sales Agreement, net of issuance costs Proceeds from Issuance of Common Stock and Warrants in Connection with Securities Purchase Agreement, Net of Issuance Costs Proceeds from issuance of common stock and warrants in connection with Securities Purchase Agreement, net of issuance costs The cash inflow from the issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs during the reporting period. Proceeds from issuance of common stock in connection with the Sales Agreement, net of issuance costs The cash inflow from the issuance of common stock and warrants in connection with At-the-Market offering, net of issuance costs during the reporting period. Proceeds From Issuance Of Common Stock And Warrants In Connection With At Market Offering Net Of Issuance Costs Stock Issued During Period Shares Issuance Of Common Stock And Warrants In Connection With At Market Offering Net Of Issuance Costs The number of shares issued during the period upon issuance of common stock and warrants in connection with at-the-market offering, net of issuance costs. Issuance of common stock in connection with the Sales Agreement, net of issuance costs (in shares) Issuance of common stock in connection with the Sales Agreement, net of issuance costs (in shares) The gross proceeds of cash inflow from issuance of common stock and warrants in connection with at-the-market offering, during the reporting period. Proceeds From Issuance Of Common Stock And Warrants In Connection With At Market Offering Gross Gross proceeds Gross proceeds Carrying amount as of the balance sheet date of research and development tax incentive receivable current. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. R&D tax credit incentive receivable Research And Development Tax Incentive Receivable Current Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustments Foreign currency translation adjustments Operating Lease, Right-of-Use Asset, Periodic Reduction Non-cash lease expense Selected Balance Sheet Detail Right-of-use Assets And Operating Lease Liabilities Lessee, Operating Leases [Text Block] Right-of-use Assets and Operating Lease Liabilities Lessee, Leases [Policy Text Block] Leases Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Restricted Stock Units, Valuation Assumptions [Table Text Block] Schedule of Share-Based Payment Award, Restricted Stock Units, Valuation Assumptions Tabular disclosure of the significant assumptions used during the year to estimate the fair value of restricted stock units, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. The following table summarizes a maturity analysis of our lease liabilities showing the aggregate lease payments as of December 31, 2024 (in thousands except weighted average data): Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] The percentage of the patients whom taking Wegovy (semaglutide injectable) discontinue therapy within second year of treatment. Percentage of patients taking Wegovy (semaglutide injectable) discontinue therapy within second year of treatment Debt instrument, term Debt instrument, interest rate, stated percentage Debt Instrument, Frequency of Periodic Payment Debt instrument, frequency of periodic payment Debt Instrument, Periodic Payment Debt instrument, periodic payment Weighted Average Exercise Price Per Share, Exercised The weighted average price per share amount at which warrant holders acquired shares when converting their share warrants into shares. Weighted Average Exercise Price Per Share, Forfeited or expired The weighted average price per share amount of warrants that were either forfeited or expired. Outstanding warrants Number of Shares, Warrants outstanding at ending balance Number of Shares, Warrants outstanding at beginning balance The number of share warrants granted during the period. Number of Shares, Issued The number of share warrants exercised during the period. Number of Shares, Exercised Number of Shares, Forfeited or expired The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the warrants agreement or that expired. Number of Shares, Warrants exercisable at ending balance The number of share warrants exercisable that may be converted into shares under warrants agreement. Number of Shares, Warrants exercisable at ending balance Exercise price per share Weighted Average Exercise Price Per Share, Warrants outstanding at ending balance Weighted Average Exercise Price Per Share, Warrants outstanding at beginning balance Weighted Average Exercise Price Per Share, Warrants exercisable at ending balance The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of warrants outstanding and currently exercisable under the warrants plan. Weighted Average Exercise Price Per Share, Warrants exercisable at ending balance Weighted Average Remaining Contractual Life, Warrants outstanding at beginning balance (in Years) Weighted Average Remaining Contractual Life, Warrants outstanding at ending balance (in Years) The weighted average remaining contractual term for warrants outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted Average Remaining Contractual Life, Warrants outstanding at ending balance (in Years) The weighted average remaining contractual term for warrants exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted Average Remaining Contractual Life, Warrants exercisable at ending balance (in Years) Weighted Average Remaining Contractual Life, Warrants exercisable at ending balance (in Years) Intrinsic value Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. Estimated aggregate intrinsic value of stock options exercisable Common share price Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Subsequent to Performance Period End Date Share-based payment award, award vesting period subsequent to performance period end date The subsequent period to performance period end date over which grantee's right to exercise award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Unrecognized compensation cost, not yet recognized Loss Contingency, Loss in Period Charge related to legal settelment Professional Services and Insurance Expense Professional services and insurance The amount of expense related to payments for professional services and insurance related expenses. Selected Balance Sheet Detail Supplemental Balance Sheet Disclosures [Text Block] Certain employees and board members This member stands for the information pertaining to "Certain employees and board of Directors". Certain employees and board of Directors [Member] Commitments and contingencies (Note 13) Gain (Loss) on Disposition of Property Plant Equipment Equipment write-off and loss on equipment disposal Shares, Issued Private Placement [Member] Independent Director, One [Member] Independent Director One Member This member stands for the information pertaining to "Independent Director, One". R&D tax credit incentive receivable Increase (Decrease) in Research and Development Tax Incentive Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from research and development tax incentive receivables. Restricted Cash and Cash Equivalents Neurostimulation Division [Member] The element represents neurostimulation division member. Change in valuation allowance (percent) Change in valuation allowance (percent) Other (percent) Other (percent) R&D tax credit from current year (percent) R&D tax credit from current year (percent) Lisa Porter [Member] The member stand for lisa por Entity Affiliated With Director [Member] This member stands for the information pertaining to "EAffiliated With Director Entity Affiliated With Directors [Member] Number of Tranche Represents the number of tranche. The components of deferred income assets and liabilities as of December 31, 2023 and 2022 are as follows (in thousands): The components of deferred income assets and liabilities as of December 31, 2025 and 2024 are as follows (in thousands): The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands) for the year ended December 31, 2023 and 2022: The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands) for the year ended December 31, 2025 and 2024: As of December 31, 2023, we had federal and apportioned state net operating loss (“NOL”) and federal and state R&D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): As of December 31, 2025, we had federal and apportioned state net operating loss (“NOL”) and federal and state R&D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): Restricted Cash Noncurrent Restricted cash Software and Software Development Costs [Member] Computer software Percentage of Weight Loss Achieved in Preclinical Data Percentage of approximate weight loss achieved in preclinical data Number of Equity Purchase Agreements Number of equity purchase agreements The number of equity purchase agreements by the reporting entity. Committed Capital Committed capital The amount of funds committed to the investors from the reporting entity. Proceeds from Issuance of Common Stock in Connection with at Market Offering Net of Issuance Costs Net proceeds from issuance of common stock in connection with the Sales Agreement, net of issuance costs The cash inflow from the issuance of common stock in connection with At-the-Market offering, net of issuance costs during the reporting period. Entity Affiliated With Director And Investor [Member] The number of shares issued or sold in connection with private sale. Sales of common stock in connection with private sale Sale Of Common Stock At Direct Offering Authorized Shares Sale of common stock authorized in direct offering Number of shares of common stock authorized to sale in dirrect offering. Proceeds From Issuance Of Common Stock In Connection With Direct Offering Gross Proceeds from issuance of common stock in connection with direct offering gross The cash inflow from the issuance of common stock in connection with direct offering gross during the reporting period. Think Equity Llc [Member] This member stands for the information pertaining to "ThinkEquity LLC". Think Equity Llc [Member] Sublease For Manufacturing Facility [Member] This member stands for the information pertaining to "Sublease For Manufacturing Facility ". Sublease For Manufacturing Facility [Member] Common stock, par value $0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 76,428 and 59,235 as of December 31, 2025 and 2024, respectively Lessee, Operating Lease, Liability, to be Paid, Year Five 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two 2027 Lessee, Operating Lease, Liability, to be Paid, Year One 2026 Proceeds From Issuance Of Common Stock In Connection With Private Sales Transaction Net Of Issuance Costs The cash inflow from the issuance of common stock in connection with private sales transaction, net of issuance costs during the reporting period. Proceeds from issuance of common stock in connection with 2025 Private Sales Transaction, net of issuance costs Proceeds From Issuance Of Common Stock In Connection With Registered Direct Offering Net Of Issuance Costs The cash inflow from the issuance of common stock in connection with registered direct offering, net of issuance costs during the reporting period. Proceeds from issuance of common stock in connection with 2025 Registered Direct Offering, net of issuance costs Proceeds From Issuance Of Common Stock In Connection With Private Placement Net Of Issuance Costs The cash inflow from the issuance of common stock in connection with private placement, net of issuance costs during the reporting period. Proceeds from issuance of common stock in connection with 2025 Private Placement, net of issuance costs Placement Agency Agreement [Member] Placement Agency Agreement [Member] This member stands for information pertaining to "Placement Agency Agreement". Transition Funding Loan Transition funding loan Amount of transition funding loan. Medium-Term Note Issuance of promissory note Sale Of Common Stock At Direct Offering Price Per Share Sale of common stock at direct offering price per share Sale of common stock at direct offering price per share. Accumulated other comprehensive income Other income, net Other Nonoperating Income (Expense) Other income (expense), net Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Depreciation of property and equipment Depreciation and amortization Property and equipment consisted of the following as of December 31, 2025 and 2024 (in thousands): Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Adjustments For Reclassification Of Foreign Currency Translation Adjustments Amount of adjustments for reclassification of foreign currency translation adjustments to reconcile net loss to net cash used in operating activities. Reclassification of foreign currency translation adjustments Depreciation Depreciation of property and equipment Expected Proceeds From Sales Of Common Stock In Connection With Private Sale Gross The expected gross proceeds of cash inflow from the issuance of common stock in connection with private sale during the reporting period. Expected proceeds from sales of common stock in connection with private sale, gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value of options granted Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Non Deductible Items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Non Deductible Items (percent) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Foreign Tax Effects Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Foreign Tax Effects (percent) Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Changes in unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Changes in unrecognized tax benefits (percent) Tax Jurisdiction of Domicile [Extensible Enumeration] Tax Jurisdiction of Domicile [Extensible Enumeration] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of loss from continuing operation before income tax Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of components of income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Pre-Tax Loss Income (Loss) from Continuing Operations before Income Taxes, Domestic Domestic Income (Loss) from Continuing Operations before Income Taxes, Foreign Foreign Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract] Income Tax Provision Federal Income Tax Expense (Benefit), Continuing Operations Federal Foreign Income Tax Expense (Benefit), Continuing Operations Foreign State and Local Income Tax Expense (Benefit), Continuing Operations State Income Tax Expense (Benefit) Total Income Tax Provision Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive securities excluded from diluted EPS Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Warrant [Member] Warrants outstanding [Member] Restricted Stock Units (RSUs) [Member] Restricted stock units outstanding [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti dilutive securities excluded from diluted EPS Effective Income Tax Rate Reconciliation [Table] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Domain] Domestic Tax Jurisdiction [Member] Foreign Tax Jurisdiction [Member] Effective Income Tax Rate Reconciliation [Line Items] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] State taxes contributed to the majority (greater than 50 percent) of the tax effect Effective Income Tax Rate Reconciliation, Percent [Abstract] Medium Term Notes Term Promissory note term Term of promissory note. Medium Term Notes Interest Rate Promissory note interest rate Rate of interest on promissory note. License and Supply Agreement [Member] License and Supply Agreement [Member] This member stands for information pertaining to "License and Supply Agreement". Okava Pharmaceuticals Inc [Member] Okava Pharmaceuticals, Inc. [Member] This member stands for information pertaining to "Okava Pharmaceuticals, Inc.". Regulatory Milestone Payments Added Regulatory milestone payments added Amount of regulatory milestone payments added Proceeds From Issuance Of Common Stock In Connection With Direct Offering Net Proceeds from issuance of common stock in connection with direct offering net The cash inflow from the issuance of common stock in connection with direct offering, net during the reporting period. Share-Based Payment Arrangement, Option [Member] Stock options outstanding [Member] Stock Options [Member] Total provision for income taxes Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Total provision for income taxes Total provision for income taxes (percent) Total provision for income taxes (percent) Total federal NOL carry-forward Total federal NOL carry-forward  State NOL carry-forward, begin expiring 2030 State NOL carry-forward, begin expiring 2030 Liabilities, other than long-term debt, noncurrent Long-term operating lease liabilities Operating Lease, Liability Total lease liabilities Total lease liabilities TOTAL ASSETS Total Assets Total assets Stock Issued During Period Value Issuance Of Common Stock In Connection With Registered Direct Offering Net Of Issuance Costs Issuance of common stock in connection with 2025 Registered Direct Offering, net of issuance costs The value of stock issued during the period upon issuance of common stock in connection with registered direct offering, net of issuance costs. Stock Issued During Period Shares Issuance Of Common Stock In Connection With Registered Direct Offering Net Of Issuance Costs Issuance of common stock in connection with 2025 Registered Direct Offering, net of issuance costs (in shares) The number of shares issued during the period upon issuance of common stock in connection with registered direct offering, net of issuance costs. Stock Issued During Period Value Issuance Of Common Stock In Connection With Private Placement The value of stock issued during the period upon issuance of common stock in connection with private placement. Issuance of common stock in connection with 2025 Private Placement Stock Issued During Period Shares Issuance Of Common Stock In Connection With Private Placement The number of shares issued during the period upon issuance of common stock in connection with private placement. Issuance of common stock in connection with 2025 Private Placement (in shares) Adjustments To Additional Paid In Capital Common Stock And Warrants Issued In Connection With At Market Offering Issuance Costs The amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing common stock and warrants in connection with at-the-market offering. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Issuance of common stock in connection with the Sales Agreement, net of issuance costs Adjustments To Additional Paid In Capital Common Stock Issued In Connection With Private Purchase Issuance Costs The amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing common stock in connection with private purchase. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Issuance of common stock in connection with private purchase, net of issuance costs Adjustments To Additional Paid In Capital Common Stock Issued In Connection With Registered Direct Offering Issuance Costs Issuance of common stock in connection with Registered Direct Offering, net of issuance costs The amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing common stock in connection with registered direct offering. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Stock Issued During Period Value Issuance of Common Stock in Connection with Private Sales Transaction Net of Issuance Costs Issuance of common stock in connection with 2025 Private Sales Transactions, net of issuance costs The value of stock issued during the period upon issuance of common stock in connection with the private sales transaction, net of issuance costs. Stock Issued During Period Shares Issuance of Common Stock in Connection with Private Sales Transaction Net of Issuance Costs Issuance of common stock in connection with 2025 Private Sales Transactions, net of issuance costs (in shares) The number of shares issued during the period upon issuance of common stock in connection with the private sales transaction, net of issuance costs. Adjustments To Additional Paid In Capital Common Stock And Warrants Issued In Connection With Securities Purchase Agreement Issuance Costs The amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing common stock and warrants in connection with securities purchase agreement. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs Adjustments To Additional Paid In Capital Common Stock Issued In Connection With Private Sales Transaction Issuance Costs Issuance of common stock in connection with Private Sales Transaction, net of issuance costs The amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing common stock in connection with private sales transaction. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, cash equivalents and restricted cash balance at beginning of year Cash, cash equivalents and restricted cash balance at end of year Promissory Note [Membber] Promissory note [Member] This member stands for information pertaining to "Promissory note".. CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments To Additional Paid In Capital Common Stock Issued In Connection With Private Placement Issuance Costs Issuance of common stock in connection with Private Placement, net of issuance costs The amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing common stock in connection with private placement. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted, weighted average grant date fair value (in dollars per share) Vested and released, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested and released, weighted average grant date fair value (in dollars per share) Forfeited/canceled Forfeited and canceled, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited/canceled Forfeited and canceled, weighted average grant date fair value (in dollars per share) Components of Deferred Tax Assets and Liabilities [Abstract] Deferred Tax: SWITZERLAND Switzerland [Member] Description Of Effective Income Tax Rate Reconciliation Foreign Juridiction Contribution Greater Than 50 Percent Tax Effect Foreign taxes contributed to the majority (greater than 50 percent) of the tax effect Indicates name of foreign jurisdiction that makes up greater than 50 percent of effect of state and local income tax. Accounting Policies [Line Items] Number of Reportable Segments Number of reporting segments Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions Increases based on tax positions related to prior years Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. Accounting Policies [Table] Disclosure of information about accounting policies. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in valuation allowance (percent) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Total Pre-Tax Loss Pre-Tax Loss Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other Other Comprehensive Income Loss Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI Realized upon Sale or Liquidation Net of Tax Reclassification from accumulated other comprehensive income to net loss related to the liquidation of subsidiary Reclassification of foreign currency translation adjustments Depreciation, Depletion and Amortization, Nonproduction Depreciation of property and equipment Depreciation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Foreign currency translation adjustments Grants Offset Against Operating Research And Development Expense Grants offset against research and development expenses The element represents grants offset against operating research and development expense. Grants Offset Against Operating General And Administrative Expense Grants offset against general and administrative expenses The element represents grants offset against operating general and administrative expense.